Persistent Systems has announced a collaboration with NVIDIA to develop and deploy AI-powered solutions tailored to the healthcare and life sciences sector, with a focus on computational drug discovery. The initiative centers on improving research efficiency and enabling scalable, production-grade AI adoption across highly regulated environments.
The collaboration combines Persistent’s engineering expertise with NVIDIA’s full-stack AI platform to help organizations transition from experimental AI use cases to operational deployment. A key outcome is the development of Generative Molecules and Virtual Screening (GenMolVS), a solution built on the NVIDIA BioNeMo platform and NVIDIA NeMo Agent Toolkit.
GenMolVS is designed to support early-stage drug discovery through AI-driven molecular simulation and virtual screening. By leveraging domain-specific models, the platform enables high-fidelity simulation of molecular behavior and supports real-time decision-making across research workflows. These capabilities allow research teams to prioritize candidates, streamline experimental planning, and translate computational outputs into laboratory validation.
The system introduces agentic AI workflows that enable continuous decision-making across multiple stages of discovery. This simulation-led approach is intended to reduce reliance on traditional trial-and-error methods, accelerate experimental cycles, and improve downstream clinical success rates.
Persistent is also integrating NVIDIA Nemotron open models to further enhance the solution’s capabilities. Deployment will rely on NVIDIA’s accelerated computing infrastructure, AI Enterprise software, and NIM microservices, supporting scalable and cost-efficient implementation in enterprise environments.
Ganesh Nathella, Executive Vice President and General Manager - HLS Business, Persistent, said, "Healthcare and Life Sciences organizations need to discover new therapies faster, but traditional R&D is too slow and labor-intensive. By combining our GenMolVS solution with NVIDIA full-stack AI platform, we enable BioPharma clients to use generative molecules and virtual screening in production so they can move from months-long experiments to AI-driven discovery in days, using simulation-led intelligence to guide real-world experimentation without compromising on scientific rigor or compliance."
John Fanelli, Vice President - Enterprise Software, NVIDIA, added, "To meet the urgent global demand for new therapies, the healthcare and life sciences industry is rapidly moving toward AI-driven computational research and discovery. By leveraging the full-stack NVIDIA AI platform, Persistent is empowering biopharma companies with production-grade agentic systems for molecular simulation and virtual screening."
Click here for the original news story.